Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of chidamide maintenance after first-line chemotherapy in responding peripheral T-cell lymphoma
ChiCTR1800017061Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by West China Hospital of Sichuan University. Primary endpoint: progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR1800017061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017061.